What is MIRM's current stock price?

MIRM (Mirum Pharmaceuticals, Inc.) is currently trading at $127.70 with a market cap of $6.41B.

What sector is Mirum Pharmaceuticals, Inc. in?

Mirum Pharmaceuticals, Inc. (MIRM) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is MIRM a good stock to buy?

Analysts have a Buy consensus on MIRM with a price target of $145.40. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

Back to Market返回行情

MIRM Mirum Pharmaceuticals, Inc.

USHealthcare

$127.70-0.68%ClosedMarket Cap: $6.41B

As of 2026-07-09 16:00

Why MIRM matters now

Mirum Pharmaceuticals, Inc. (MIRM) is a US stock in Healthcare. The latest InvestLog snapshot shows $127.70 with -0.68% on the session and $6.41B in market capitalization; recent performance reads 1-month +12.00% and YTD +35.62%.

The latest financial table shown here is Q1 2026, with revenue of $159.9M, net income of $-790.2M, and EPS of $-13.43. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3.2%.

The latest indexable market news headline is "Mirum Pharmaceuticals: This Liver Disease Juggernaut Just Broadened Its Portfolio" from Seeking Alpha.

Additional event context on this page matters because analyst consensus is Buy with a median target of $143.50; recent insider activity includes Howe Jolanda filing S-Sale. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

—

PEG

—

P/B

26.00

P/S

9.44

EV/EBITDA

-7.06

DCF Value

$-3,428.61

FCF Yield

-3.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

81.4%

Operating Margin

-12.3%

Net Margin

-140.2%

ROE

-289.3%

ROA

-89.7%

ROIC

-11.3%

Financials

Period	Revenue	Net Income	EPS
Q1 2026	$159.9M	$-790.2M	$-13.43
Q4 2025	$148.9M	$-5.7M	$-0.12
FY 2025	$521.3M	$-23.4M	$-0.47
Q3 2025	$133.0M	$2.9M	$0.05

Analyst Ratings

Consensus

Buy

Target (Consensus)

$145.40

Target (Median)

$143.50

Target Range

$118.00 - $185.00

Strong Buy: 4Buy: 10Hold: 0Sell: 0Strong Sell: 0

CitizensMarket Outperform

2026-06-15

Morgan StanleyOverweight

2026-06-11

RBC CapitalOutperform

2026-05-07

TD CowenBuy

2026-05-07

BairdOutperform

2026-05-07

Trading Activity

Insider Trades

Howe Jolandaofficer: SVP, GLOBAL CONTROLLER

Sell2026-06-18

GREY MICHAEL Gdirector

Sell2026-06-17

GREY MICHAEL Gdirector

Sell2026-06-17

Fischer Laurentdirector

Sell2026-06-17

Fischer Laurentdirector

Sell2026-06-17

Related Stocks

ACAD

ACADIA Pharmaceuticals Inc.

Dyne Therapeutics, Inc.

$3.10B

LGND

Ligand Pharmaceuticals Incorporated

$5.08B

Latest News

Mirum Pharmaceuticals: This Liver Disease Juggernaut Just Broadened Its PortfolioSeeking Alpha · 2026-07-04

Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?Zacks Investment Research · 2026-06-29

Biotech ETF Index Surges 10% After RebalanceETF Trends · 2026-06-25

MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)Zacks Investment Research · 2026-06-17

MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)Zacks Investment Research · 2026-06-16

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.51

Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.